Sirnaomics, a US-China Biopharma, Starts Trial of RNAi Candidate

Sirnaomics, a US-China company developing RNA-interference drugs, has begun a Phase II trial of its leading siRNA therapeutic candidate, STP705 (Cotsiranib®). An anti-fibrosis molecule, Cotsiranib is being tested as a treatment for hypertrophic scar. Sirnaomics filed to begin China trials of the candidate in January 2016. The company is headquartered in Maryland, with subsidiaries in Suzhou and Guangzhou. It partnered with Guangzhou Xiangxue Pharma in 2011 to develop Cotsiranib in China through Phase II. More details.... Share this with colleagues: // //